Anti-Mouse CD16/CD32 Antibody (2.4G2)
Based on 1 Customer Validation
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.
For research use only. We do not sell to patients.
- Purity : 97.02%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG2b kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CD16/CD32
In Vitro
Anti-Mouse CD16/CD32 Antibody (2.4G2) significantly inhibits the binding of MDALDL to J774 cells[1].
Anti-Mouse CD16/CD32 Antibody (2.4G2) (24 h) significantly reduces the production of foam cells by blocking FcγRs in RAW264.7 cells[1].
Anti-Mouse CD16/CD32 Antibody (2.4G2) (0.01 mg/mL, 6 days) inhibits anti-body secreting cells (ASC) formation and also reduces T cell cytokine levels such as IFN-γ, IL-10 and TNF-α in T cells from the spleen of F8-/- mice[2].
Anti-Mouse CD16/CD32 Antibody (2.4G2) (0.01 mg/mL, 4 days) interferes with the uptake and presentation of FVIII immune complexes by B cells from the spleen of F8-/- mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Anti-Mouse CD16/CD32 Antibody (2.4G2) (100 μg, i.p., single dose, 24 h before injection of MWReg30) reverses the pathological effects of rat antimouse platelet MWReg30 in NMRI mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:γ-/- mice (2-4 months)[3]
-
Dosage:8 μg/g
-
Administration:Intravenous injection (i.v.), single dose, 1 h before injection of MAb 6A6
-
Result:Maintained a baseline platelet count of 86%, significantly higher than the control group.
-
Animal Model:NMRI mice (5-7 weeks)[4]
-
Dosage:100 μg
-
Administration:Intraperitoneal injection (i.p.), single dose, 24 h before injection of MWReg30
-
Result:Prevented MWReg30 induced hypothermia and acute lung injury.
Gene ID
14131 [NCBI]
Accession
P08508
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo Fc receptor blocking; Fc receptor blocking, flow cytometryFc receptor blocking, immunofluor
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD16/CD32 Antibody (2.4G2)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhu X, et al. Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice. J Immunol. 2014 Sep 1;193(5):2483-95. [Content Brief]
[2]. Vollack N, et al. CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro. Thromb Haemost. 2017 Aug 30;117(9):1679-1687. [Content Brief]
[3]. Clynes R, et al. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995 Jul;3(1):21-6. [Content Brief]
[4]. Nieswandt B, et al. Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood. 1999 Jul 15;94(2):684-93. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD16/CD32 Antibody (2.4G2) Related Classifications
HY-P99125 Related Classifications
Powered by Bioz